Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr;85(2):156-160.

Preliminary study of urinary excretion of liver-type fatty acid-binding protein in a cat model of chronic kidney disease

Akiko Watanabe  1 , Keiichi Ohata  1 , Tsuyoshi Oikawa  1 , Takeshi Sugaya  1 , Masao Miyazaki  1 , Hiroshi Satoh  1 , Masaaki Katayama  1
Affiliations

Preliminary study of urinary excretion of liver-type fatty acid-binding protein in a cat model of chronic kidney disease

Akiko Watanabe et al. Can J Vet Res. 2021 Apr.

Abstract
in English, French

Urinary liver-type fatty acid-binding protein (uL-FABP) is a clinically useful biomarker for monitoring chronic kidney disease (CKD) in humans. However, long-term monitoring of uL-FABP in CKD cats has not been reported. The objective of this preliminary study was to investigate whether the urinary excretion of L-FABP could predict the deterioration of renal function in 2 CKD model cats. Urinary liver-type fatty acid-binding protein (uL-FABP) increased before standard renal biomarkers, including serum creatinine, blood urea nitrogen, and symmetric dimethylarginine, in 1 cat with deteriorating renal function, but remained low and relatively stable in another cat with stable renal function. Our results suggest that uL-FABP is a potential clinical biomarker for predicting the progression of CKD in cats, as it is in humans.

La protéine urinaire de liaison aux acides gras de type hépatique (uL-FABP) est un biomarqueur cliniquement utile pour la surveillance de l’insuffisance rénale chronique (MRC) chez l’homme. Cependant, aucune surveillance à long terme de l’uL-FABP chez les chats atteints d’IRC n’a été signalée. L’objectif de cette étude préliminaire était de déterminer si l’excrétion urinaire de L-FABP pouvait prédire la détérioration de la fonction rénale chez deux chats modèles de CKD. La protéine uL-FABP a augmenté avant les biomarqueurs rénaux standards, y compris la créatinine sérique, l’azote uréique sanguin et la diméthylarginine symétrique, chez un chat dont la fonction rénale se détériorait, mais est restée faible et relativement stable chez un autre chat dont la fonction rénale était stable. Nos résultats suggèrent que l’uL-FABP est un biomarqueur clinique potentiel pour prédire la progression de l’IRC chez le chat, comme c’est le cas chez l’homme.(Traduit par Docteur Serge Messier).

PubMed Disclaimer

Figures

Figure 1
Figure 1
Time course of urinary liver-type fatty acid-binding protein (uL-FABP) and common renal function markers, including serum creatinine (sCre), blood urea nitrogen (BUN), and symmetric dimethylarginine (SDMA) in feline chronic kidney disease (CKD) models. A, C, E, and G — Cat 1. B, D, F, and H — Cat 2. The left ureter was ligated on day 0. The left ureter was released and anastomosed to the bladder mucosa on day 28. Right nephrectomy was conducted on day 42.
Figure 2
Figure 2
Histopathological images of Masson’s trichrome staining in CKD model cats. A — Right non-obstructed kidney tissues of Cat 2. B — Left obstructed kidney of Cat 1. Mild interstitial fibrosis, interstitial inflammation, and tubular atrophy were observed. C — Left obstructed kidney of Cat 2. Moderate interstitial fibrosis, interstitial inflammation, tubular dilation, and tubular atrophy were observed. Bar = 50 μm.
See this image and copyright information in PMC

References

    1. Bartlett PC, Van Buren JW, Neterer M, Zhou C. Disease surveillance and referral bias in the veterinary medical database. Prev Vet Med. 2010;94:264–271. - PubMed
    1. Marino CL, Lascelles BDX, Vaden SL, Gruen ME, Marks SL. Prevalence and classification of chronic kidney disease in cats randomly selected from four age groups and in cats recruited for degenerative joint disease studies. J Feline Med Surg. 2014;16:465–472. - PMC - PubMed
    1. Polzin DJ. Evidence-based step-wise approach to managing chronic kidney disease in dogs and cats. J Vet Emerg Crit Care. 2013;23:205–215. - PubMed
    1. Kamijo A, Sugaya T, Hikawa A, et al. Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol Cell Biochem. 2006;284:175–182. - PubMed
    1. Katayama M, Ohata K, Miyazaki T, et al. Renal expression and urinary excretion of liver-type fatty acid-binding protein in cats with renal disease. J Vet Intern Med. 2020;34:761–769. - PMC - PubMed

LinkOut - more resources